News and reflections from the world of AI

Aiforia adds fourth CE-IVD marked clinical AI Model to its rapidly expanding portfolio of novel tools for cancer diagnostics

Aiforia is providing a uniquely comprehensive approach to breast cancer diagnostics as the majority of cases express ER and/or PR. Therefore, the two are considered to be the most significant biomarkers involved in the evaluation of breast cancer.

Aiforia Technologies Plc appoints Vice President of Sales for Europe

Aiforia has appointed Tamas Regenyi as Vice President of Sales, Europe. The position will be essential to driving Aiforia’s business strategy in the region; focusing on accelerating growth in Aiforia’s established preclinical market in acquiring large customers in the pharmaceutical industry as well as advancing Aiforia’s position in the clinical diagnostics market for pathology.

Aiforia aims to set a new industry standard for customer support with the launch of its one of a kind Aiforia Community Platform

Earlier this week Aiforia Technologies launched the Aiforia Community Platform — one of the only available platforms of this nature, for pathologists and scientists utilizing AI for image analysis software in preclinical and clinical settings. The company’s users, ranging from some of the world’s largest pharmaceutical companies to the world’s top ranked hospitals and medical institutions, now ...

Aiforia expands its portfolio of CE-IVD marked clinical pathology solutions with new AI model for breast cancer diagnostics

Aiforia Technologies Plc, Press Release, 20 April, 2022 at 09.30 a.m. EEST. Aiforia Technologies Plc announces the CE-IVD marking of the Aiforia® Clinical AI Model for Breast Cancer; ER. Adding to its repertoire of CE-IVD marked clinical AI models for cancer diagnostics, the new AI model automates the calculation of estrogen receptors (ER) — a group of proteins present in the majority of breast ...

Aiforia signs agreement with South Korean biotech company to augment its novel drug discovery platform with AI

The two companies announced an agreement to add Aiforia’s artificial intelligence technology to Genuv’s ATRIVIEW® proprietary drug discovery platform, used to screen both existing drugs and new substances for neuroprotective and neuroregenerative effects. ATRIVIEW® was used to discover Genuv’s leading drug candidate, SNR1611, which has shown the ability to restore CNS function in preclinical ...

Aiforia appoints VP of Sales, Americas

Aiforia, a software company providing pathologists with AI-based solutions for clinical diagnostics and preclinical analysis, today announced that Marco Comianos has joined the company as VP of Sales, Americas. Comianos will oversee sales efforts, as well as driving new business, revenue growth, and more partnerships with top hospitals and pharma companies across the region.